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Abstract
Background: The tubule-interstitial fibrosis is the hallmark of progressive renal disease and is strongly associated with
inflammation of this compartment. Heme-oxygenase-1 (HO-1) is a cytoprotective molecule that has been shown to be
beneficial in various models of renal injury. However, the role of HO-1 in reversing an established renal scar has not yet been
addressed.
Aim: We explored the ability of HO-1 to halt and reverse the establishment of fibrosis in an experimental model of chronic
renal disease.
Methods: Sprague-Dawley male rats were subjected to unilateral ureteral obstruction (UUO) and divided into two groups:
non-treated and Hemin-treated. To study the prevention of fibrosis, animals were pre-treated with Hemin at days -2 and -1
prior to UUO. To investigate whether HO-1 could reverse established fibrosis, Hemin therapy was given at days 6 and 7 post-
surgery. After 7 and/or 14 days, animals were sacrificed and blood, urine and kidney tissue samples were collected for
analyses. Renal function was determined by assessing the serum creatinine, inulin clearance, proteinuria/creatininuria ratio
and extent of albuminuria. Arterial blood pressure was measured and fibrosis was quantified by Picrosirius staining. Gene
and protein expression of pro-inflammatory and pro-fibrotic molecules, as well as HO-1 were performed.
Results: Pre-treatment with Hemin upregulated HO-1 expression and significantly reduced proteinuria, albuminuria,
inflammation and pro-fibrotic protein and gene expressions in animals subjected to UUO. Interestingly, the delayed
treatment with Hemin was also able to reduce renal dysfunction and to decrease the expression of pro-inflammatory
molecules, all in association with significantly reduced levels of fibrosis-related molecules and collagen deposition. Finally,
TGF-b protein production was significantly lower in Hemin-treated animals.
Conclusion: Treatment with Hemin was able both to prevent the progression of fibrosis and to reverse an established renal
scar. Modulation of inflammation appears to be the major mechanism behind HO-1 cytoprotection.
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Introduction
The tubule-interstitial space plays an important role in the
progression of chronic renal diseases [1]. Tubule-interstitial
changes, including tubular degeneration and interstitial cell
infiltration, are a hallmark of common progressive chronic diseases
that lead to renal failure [2].
A well-characterized experimental model of renal injury that
leads to tubule-interstitial fibrosis is the unilateral ureteral
obstruction (UUO). The obstruction of urinary flow leads to
release of chemoattractant molecules and growth factors, upregu-
lation of adhesion proteins and degradation of basement
membrane matrix proteins [3]. Moreover, a few hours after the
obstruction of urine flow, blood-derived macrophages accumulate
in the tubule-interstitial space (in healthy renal cortex, the
presence of these cells is rare). This cellular infiltration is driven
by local expression of molecules such as monocyte chemoattrac-
tant protein-1 (MCP-1) and osteopontin [4]. Infiltrating cells
release pro-inflammatory cytokines such as TNF-a, IL-6 and IL-
1b that activate resident fibroblasts and epithelial tubular cells to
initiate the process of epithelial-to-mesenchymal transition (EMT),
a process in which polarized epithelial cells undergo biochemical
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changes and assume a mesenchymal cell phenotype. EMT is
associated with release of fibroproliferative molecules, such as
TGF-b and PAI-1, and production of extracellular matrix
proteins, such as fibronectin and types I and III collagens [5,6].
The actual challenge is to halt this process in order to avoid end-
stage renal failure.
Heme oxygenase-1 (HO-1) is the inducible isoform of the rate-
limiting enzyme involved in the degradation of heme. It is
responsible for converting heme to carbon monoxide, billiverdin
(which is rapidly converted to bilirubin), and free iron (which leads
to the induction of ferritin) [7]. HO-1 is strongly induced by
oxidative stress and shows cytoprotective effects by the anti-
inflammatory, anti-apoptotic, and anti-proliferative actions of its
end by-products [8]. Recent studies showed that HO-1 induction
is protective in many acute and chronic renal insults
[9,10,11,12,13,14]. To clarify the role of HO-1 in fibrotic process,
Kie et al showed that HO-1 knockout mice had significantly
greater fibrosis 7 days after UUO compared with wild-type mice,
with more extensive EMT [15]. This cytoprotective role of HO-1
was not totally unveiled and may be linked to a modulation of the
inflammatory process present in fibrosis.
Recently, some studies have suggested that renal fibrosis could
be reversible [16,17]. Until now, it has been proposed that
blockade of the renin-angiotensin-aldosterone system (RAS) is the
most effective way to reduce fibrosis [18]. Here, we hypothesize
that induction of HO-1, in addition to protecting the kidney from
developing fibrosis, can also reverse an established renal scar with
improvement in function. Because inflammation is a major
component of progression of renal function in chronic renal
failure, and HO-1 has evident anti-inflammatory activity, we
postulated that this cytoprotection is mainly due to the ability of
HO-1 to modulate the immune response.
Materials and Methods
Ethics Statement
The animals used in this work were housed in individual
standard cages and were kept on a 12 h light/dark cycle in a
temperature-controlled room at 21–23uC, with free access to water
and food. All procedures were approved by the internal ethical
committee of the Federal University of Sa˜o Paulo (Document nu
0029/2009).
Animals
Male Sprague-Dawley rats, aged 8–12 weeks (300–350 g), were
purchased from Federal University of Sa˜o Paulo and State
University of Campinas Animal Facility Center.
Drug
Hemin was purchased from Frontier Scientific (Logan, USA),
and was dissolved in 0.5 mol/L NaOH, titrated to pH 7.4 with
HCl, and made isotonic with distilled water and NaCl. The
solution was prepared in darkness just before use and protected
from light. Animals were treated with 10 mg/Kg by intraperito-
neal (i.p.) injection, according to the protocol described below.
Experimental model of unilateral ureteral obstruction
(UUO)
Rats were briefly anesthetized with Ketamine–Xylazine (Agri-
brands do Brazil, Sa˜o Paulo, Brazil) unless otherwise stated. On
day 0, UUO was performed by complete ligation of the left ureter
with 4-0 silk at 2 points, and an incision made between the points
of ligation. Animals were placed in single cages and warmed by
indirect light until completely recovered from anesthesia. After
recovery, animals were kept under normal housing condition until
sacrifice.
Study design
To check the protective effect of HO-1 upregulation, animals
subjected to UUO were either treated or not treated with Hemin.
The Hemin was administered at 10 mg/Kg 2 days before surgery.
In these studies, animals were sacrificed 7 and 14 days after
surgery.
To investigate the capacity of HO-1 in reversing the renal
fibrosis, animals were again subjected to UUO and treated with
10 mg/Kg of Hemin i.p. on days 6 and 7 after the surgery.
Animals were sacrificed 14 days after the obstruction.
Control animals were subjected to the surgical procedure
without ureteral ligation (sham-operated animals). In each study,
10 animals were used for each timepoint assessed.
Renal Function Outcomes
Blood was collected for serum creatinine measurements, and
kidneys harvested for histological, protein and gene expression
analyses. Animals were placed in metabolic cages for 24-hours to
collect urine. Urinary protein/creatinine ratios were measured in
samples collected from the obstructed pelvis and from the bladder
at 7 and 14 days post-surgery. All samples were analyzed by
colorimetric assays using commercially-purchased kits (Creatinine
and Sensiprot Kits, Labtest, Minas Gerais, Brazil). To estimate the
urinary albumin concentration, 10 ml of urine were diluted in
sample buffer v/v, run on a 10% SDS-polyacrylamide electro-
phoresis gel and then stained with commassie blue. The gel was
photographed using the software GeneSnap (Syngene, Frederick,
USA), and quantification was performed by Gene Tools (Syngene,
Frederick, USA).
To performe the clearance studies, each designated animal was
anesthetized intraperitoneally with 50 mg/kg body weight (BW) of
sodium thiopental. The trachea was cannulated with a polyeth-
ylene (PE)-240 catheter, and spontaneous breathing was main-
tained. To control mean arterial pressure and allow blood
sampling, a PE-60 catheter was inserted into the right carotid
artery. To collect urine samples, a suprapubic incision was made,
and the urinary bladder was cannulated with a PE-240 catheter.
After the surgical procedure, a loading dose of inulin (100 mg/kg
BW diluted in 0.9% saline) was administered through the jugular
vein. Constant infusion of inulin (10 mg/kg BW) was then started
and continued at 0.04 ml/min throughout the experiment
(infusion bomb Harvard Apparatus (Holiston, MA, EUA). A total
of three urine samples were collected at 30-minute intervals. Blood
samples were obtained at the beginning and end of the
experiment. Blood and urine inulin were determined using the
anthrone method. Also, blood pressure were measured during
clearances experiments through an invasive pressure monitor
(Biopac Systems Inc, Aero Camino Goleta, CA, USA), within the
carotid artery and kidneys weight were determined after the
animals sacrifice. Blood samples were collected during inulin
clearance experiments and analyzed with ABL800 FLEX Blood
Gas Analyzer (Radiometer America Inc, Westlake, OH, USA).
Tubule-interstitial fibrosis quantification
Formaldehyde-fixed paraffin sections of the kidneys were
stained with Picrosirius. Renal histomorphometric analyses were
made by two ‘‘blinded’’ renal histologists. The extent of renal
interstitial expansion was quantitatively evaluated in Picrosirius
stained sections by a point-counting technique in consecutive
microscopic fields at a final magnification of 100X under a 176-
point grid with the help of the KS300 program (Zeiss). For
HO-1 and Renal Fibrosis
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Picrosirius staining, 0.1 g of Sirius red and 100 ml of saturated
picric acid solution were used to stain 3 mm- thick paraffin
sections. Histological sections were deparaffinized with xylol and
subsequently hydrated with absolute alcohol (4X) and running
water. The sections were then immersed in saturated picric acid
solution for 15 minutes and then in Picrosirius for 20 more
minutes. Counter-staining was carried out with Harris hematox-
ylin. Picrosirius stained sections were analyzed by an Olympus
BX50 microscope with an Olympus camera attached. Manual
shots were taken of the cortex, magnified 40X, and observed
under polarized light. Photos of at least 5 different fields in each
slide were taken, and structures such as the glomeruli, subcapsular
cortex, large vessels and medulla were excluded. The pictures were
digitalized (HP Scanjet 2400) and then the interstitial volume of
collagen in the cortex compared to the overall cortex area was
quantified by morphometry.
For the morphometric analysis, the Image Processing and
Analysis in Java, Image J software was used. The result of the
analysis is represented by percentage, and refers to the proportion
of the interstitial volume of collagen in the cortex to the total
cortical interstitial volume, and then the arithmetic mean of the
analyzed fields was calculated for each slide. Assessment of the
interstitial fibrosis volume obtained by morphometric analysis of
the digital image stained with Picrosirius was based on previous
studies [19].
Elisa Assay for TGF-b
Total TGF-b1 protein was measured by ELISA (TGFb1
EmaxH, Promega, Madison, USA). Kidney cells were lysed in
RIPA buffer and protein levels quantified by DC Protein Assay
(Bio-Rad, Hercules, USA). After overnight coating of a 96-well
plate with a primary antibody, TGF-b1 was detected in cell lysates
Figure 1. Treatment with Hemin upregulates HO-1 and leads to improved renal functional outcome. (A) RelativemRNA expression of HO-
1 in obstructed kidneys from untreated (UUO) and treated (Hemin) animals, 7 and 14 days after surgery. mRNA values from samples are relatively expressed
to Control animals, which were assigned a value of 1. * p,0,001 vs. UUO, ** p,0,05 vs. UUO 7 days and#p,0,001 vs. Hemin 7 days. (B) Urine protein values
(mg/dL) from bladder of control, UUO and Hemin-treated animals. *p,0,05 vs. Hemin, # p,0,05 vs. Control and **p,0,05 vs. Hemin. (C) Urine protein/
creatinine ratio of obstructed pelvis collected by puncture at time of sacrifice from UUO and Hemin-treated animals. *p,0,05 vs. UUO 14 days. (D) Urine
albumin excretion analysis. The top panel represents an SDS-PAGE showing the molecular weight of albumin. The graph below expresses the digital optic
quantification from the SDS-PAGE. All data are expressed as average 6 s.e.m.
doi:10.1371/journal.pone.0014298.g001
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using a secondary antibody. The system uses horseradish
peroxidase-conjugated secondary antibody and a single-compo-
nent TMB substrate for the final chromogenic detection of bound
TGF-b1. Using this assay, biologically active TGFb-1 in tissue
culture supernatants, plasma, serum or urine can be detected in
the range of 15.6–1,000 pg/ml. Results are expressed as ng/mg of
TGF-b protein.
Gene Profiles
Kidney samples were snap-frozen in liquid nitrogen. Total RNA
was isolated from kidney tissue using the TRIzol Reagent
(Invitrogen, Carlsbad, Calif) and protocol according to Invitrogen.
RNA concentrations were determined by spectrophotometer
readings at absorbance 260 nm. First-strand cDNAs were
synthesized using the MML-V reverse transcriptase (Promega,
Madison, Wisc). RT-PCR was performed using the SYBR Green
real-time PCR assay (Applied Biosystem, USA) for the following
molecules: Hypoxanthine Guanine Phosphoribosyl Transferase
(HPRT) (sense) 59-CTC ATG GAC TGA TTA TGG ACA GGA
C-39, (antisense) 59-GCA GGT CAG CAA AGA ACT TAT AGC
C-39; MCP-1 (sense) 59-AAG AGA ATC ACC AGC AGG T-39,
(antisense) 59-TTC TGG ACC CAT TCC TTA TTG G-39;
Collagen type I (sense) 59-TGG CCA AGA AGA CAT CCC
TGA AGT-39, (antisense) 59-AGA TCA GGT TTC CAC GTC
TCA CCA-39; Collagen type III (sense) 59-ATG AGC TTT GTG
CAA TGT GGG ACC-39, (antisense) 59-ACT GAC CAA GGT
AGT TGC ATC CCA-39; PAI-1 (sense) 59-GAC TGA CAT CTT
CAG GTC AAC CC-39, (antisense) 59-TCA CCT CGA TCT
TGA CCT TTT GT-39, Catalase (sense) 59 CAC CAT AGC
CAG TGC TCT GC 39, (antisense) 59 TGG CAA TGT TCT
CAC ACA GG 39 and TGF-b (sense) 59-TCA GTC CCA AAC
GTC GAG GT-39, (antisense) 59-GCT GTG CAG GTG TTG
AGC C-39. RT-PCR was performed using the Taqman real-time
PCR assay (Applied Biosystem, USA) for the following molecules:
HPRT (Rn01527838_g1), TNF-a (Rn99999017_m1), IL-1b
(Rn00580432_m1), IL-6 (Rn00561420_m1), HO-1 (Rn00561387
_m1 and Hs01110250_m1), HIF-1a (Rn00577560_m1), Fibro-
nectin (Rn00569575_m1), a-SMA (Hs00426835_g1), E-cadherin
(Hs01023894_m1) and GAPDH (Hs03929097_g1). Cycling con-
ditions were as follows: 10 minutes at 95uC followed by 45 cycles
at 20 seconds each at 95uC, 20 seconds at 58uC, and 20 seconds at
72uC. Analysis used Sequence Detection Software 1.9 (SDS).
mRNA expression was normalized to HPRT or GAPDH
expression.
Western blot Analysis
Kidney cells were lysed in RIPA buffer, run on a 10% SDS-
polyacrylamide electrophoresis gel and transferred onto a
nitrocellulose membrane (Hybond C Extra, Amershan Bioscienc-
es, Little Chalfon, USA). Membranes were incubated with
primary goat anti–rat HO-1 (Sigma) antibody, using manufactur-
er-recommended dilutions, followed by a peroxidase-conjugated
mouse anti-goat IgG antibody (Jackson ImmunoResearch Labo-
ratories, WestGrove, USA). HRP activity was detected using
enhanced chemiluminescence. The membrane was stripped and
probed with mouse primary anti–b-tubulin or anti-b-actin
antibody (Sigma, St. Louis, USA) to confirm and estimate the
loading and the transfer. We used the software, GeneSnap
(Syngene, USA) and Gene Tools (Syngene, USA), to analyze the
bands.
Immunohistochemistry (IHC)
Localization of type I collagen (diluted 1:300; Abcam, USA) and
FSP-1 (diluted 1:600, A5114, DAKO, Ely, UK) were assessed in
paraffin-embedded tissue sections. As described previously, the
slides were deparaffinized, rehydrated and subjected to a Tris-
Table 1. UUO surgery does not alter serum creatinine values.
Control UUO Hemin
Preview treatment with Hemin significance
Basal 0,6860,01 0,6660,02 0,6660,04 NS
14 days 0,6860,01 0,6860,04 0,6860,02 NS
Late treatment with Hemin
Basal 0,6060,03 0,6160,05 0,6360,04 NS
14 days 0,6060,02 0,5960,02 0,6160,03 NS
Serum creatinine values (mg/dL) from control, UUO and Hemin-treated animals.
Blood samples were collected before surgery (basal) and after sacrifice (14 days).
Serum creatinine values (mg/dL), expressed as average 6 s.e.m., from the
following groups: control, animals subjected to UUO, and animals subjected to
UUO and treated with Hemin. Data indicate values from the pre-treatment
protocol, when Hemin was administered before obstruction surgery, and the late
treatment protocol, when the drug was administered after established fibrosis.
doi:10.1371/journal.pone.0014298.t001
Figure 2. Influence of Hemin treatment on inulin clearance, mean arterial blood pressure and kidneys weight. (A) Inulin clearance was
estimated by 100 g of body weight (average 6 s.e.m.). No difference between the groups were observed. (B) Mean arterial blood pressure were
assessed during inulin clearance experiments (average 6 s.e.m.) * p,0,05 vs Control and Hemin. (C) After sacrifice obstructed and contralateral
kidneys were removed and weighed. After, a ratio between the kidneys were performed (average 6 s.e.m.). * p,0,05 vs Control and # p,0,05 vs
UUO.
doi:10.1371/journal.pone.0014298.g002
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EDTA (pH 9) antigen retrieval solution at 95uC. The endogenous
peroxidase activity was blocked with 3% hydrogen peroxide, and
sections were additionally blocked with Protein Block Solution
(DAKO). Slides were incubated with a primary antibody or
isotype non-specific IgG as negative control reagent, followed by
incubation with the labeled polymer Envision (DAKO), using two
Figure 3. Upregulation of HO-1 promotes less fibrotic tissue deposition in the obstructed kidney. (A) Picrosirius staining from control
kidneys and obstructed kidneys of UUO and Hemin-treated animals. Panels a, b, c, d, and e show the tissue when seen using a light microscope and
the panels f, g, h, i, and j show the same tissue observed using polarized light. (B) Immunohistochemistry (IHC) for localization of FSP-1 (panels a, b, c,
d, and e) and Collagen type I (panels f, g, h, i, and j) from control kidneys and obstructed kidneys of UUO and Hemin-treated animals. (C) Fibrosis area
quantification from picrosirius staining (percentage of analyzed field) from groups represented in Figure 2A. The data is expressed as average6 s.e.m.
* p,0,05 vs. Control and Hemin and #p,0,001 vs. Control and Hemin. (D) A representative graph showing IHC quantification for FSP-1. *p,0,001 vs
Control and Hemin and # p,0,05 vs Control. (E) Representative graph quantification for Collagen type 1 IHC. *p,0,001 vs Control and Hemin and#
p,0,05 vs Control.
doi:10.1371/journal.pone.0014298.g003
HO-1 and Renal Fibrosis
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sequential 30-minute incubations at room temperature. Staining
was completed by a 1–3 minute incubation with 3,39-diamino-
benzidine (DAB)+ substrate-chromogen, which stains the specific
antigen brown. Hematoxylin counterstaining was also done.
Bioplex
Kidney cells were lysed in RIPA buffer with protease inhibitor.
A Bio-Plex rat Plex cytokine assay kit (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA) was used to test samples for the presence of 6
cytokines. The assay was read on the Bio-Plex suspension array
system, and the data were analyzed using Bio-Plex Manager
software version 4.0. Standard curves ranged from 32,000 to
1.95 pg/mL.
Cell Culture
HK-2 cells were purchased from American Type Culture
Collection (ATCC No. CRL-2190, Manassas, VA, USA). Cells
were routinely cultured on 10-cm culture dishes from Sarstedt
(Manassas,VA, USA). In the culture medium DMEM-F12
(GIBCO, Invitrogen, Lofer, Austria) was added 100 U/ml
penicillin, and 100 mg/ml streptomycin (GIBCO). Cells were fed
three times weekly and subcultivated by trypsinization when near
Figure 4. Effects of HO-1 upregulation on inflammatory molecule gene expression after unilateral ureter obstruction. Kidney samples
from obstructed kidneys of UUO and Hemin-treated animals were processed and RT-PCR performed for TNF-a (panel A), IL-6 (panel B), IL-1b (panel C),
and MCP-1 (panel D). Kidney tissue from normal rats was used as a control, and assigned a value of 1.Data are shown as average6 s.e.m. * p,0,05 vs.
UUO and # p,0,05 vs. Hemin 7 days.
doi:10.1371/journal.pone.0014298.g004
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confluence. Cells were trypsinized and seeded onto 6-well plates.
Cells were grown to 80% confluence before treatment to best
represent the in vivo situation of a differentiated epithelial
monolayer.
The drugs stock was diluted immediately before treatment and
added to the growth medium. Solvent (NaOH 0,1 M) concentra-
tions were at a maximum of 0.2% in all treatment groups,
including controls. TGF-b1 (10 ng/ml) was used. After cultivated
for 24 h in culture medium serum-deprived, cells were incubated
for 24 hours with Hemin (1, 5, 15 or 50 mM). After that, cells were
washed twice with PBS and then submitted to total RNA and
protein extraction.
Statistics
The data were described as mean6S.E.M. Differences among
groups were compared using ANOVA (with Tukey post-test) and
students t-test. Significant differences were regarded as p,0.05.
All statistical analyses were performed with the aid of GraphPad
PRISMH.
Results
Treatment with Hemin improves renal functional
outcome
Initially, we aimed to see whether the treatment with Hemin
could induce HO-1 expression. For this purpose, we treated
human proximal tubular epithelial cells (HK-2) with different
concentrations of Hemin for 24 hours. As observed on Figure S1
(Panels A and B), Hemin markedly enhanced HO-1 protein
expression on these cells.
Next, we determined whether HO-1 induced by Hemin could
indeed protect the kidneys from the development of progressive
fibrosis. So, we moved to in vivo experiments and the animals were
treated with Hemin prior to surgery. UUO induced HO-1 in the
kidneys of animals treated with and without Hemin. However, in
the Hemin-treated group, there was a significant increase in HO-1
when compared to the untreated group at 7 days after ureteral
ligation. After 14 days of surgery, the expression of HO-1 was
lower in both groups, but even at that time, there was still greater
expression in the treated group (Figure 1A).
Once we verified that the treatment promotes upregulation of
the HO-1 enzyme, we evaluated the cytoprotective role of HO-1.
Serum creatinine levels were not different between the groups
(Table 1), also confirmed by inulin clearance measurements
(Figure 2A). Moreover, we observed a significant increase in
arterial blood pressure in UUO group, compared to control and
Hemin-treated animals (Figure 2B).
The obstructed and contralateral kidneys were also weighed and
a ratio was calculated. In UUO group, this ratio was significantly
higher than in control animals and in Hemin-treated ones
(Figure 2C). The metabolic evaluation showed no difference
among the groups (Figure S2, panels A–F). We also noticed a
marked decrease in proteinuria in Hemin-treated animals, which
was evident from the first timepoint until sacrifice (Figure 1B),
Figure 5. Hemin treatment leads to a decreased kidney protein expression (average ± s.e.m.) of TNF-a (panel A), IL-1b (panel B),
IFN-c (panel C), IL-6 (panel D) and IL-2 (panel E) and enhanced protein expression of IL-10 (panel F). * p,0,05 vs UUO and Hemin, #
p,0,05 vs UUO and ** p,0,05 vs control and UUO.
doi:10.1371/journal.pone.0014298.g005
HO-1 and Renal Fibrosis
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possibly correlating with arterial blood pressure measurements.
Next, we measured the proteinuria present in the obstructed
pelvis. As these samples were collected by puncture, we expressed
the results by dividing the urine protein levels by the urinary
creatinine levels. We observed a lower urinary protein:creatinine
ratio after 7 days in the Hemin-treated group, and it was
significantly reduced 14 days after UUO (Figure 1C).
To check whether the proteinuria observed after surgery was
mainly due to the fraction of filtered albumin, we used a 10%
SDS-PAGE Coomassie stained gel to indirectly estimate the
amount of this protein. The group of animals subjected to UUO
that did not receive any treatment had much greater albuminuria
than the Hemin-treated animals (Figure 1D). Furthermore, we also
examined the extent of interstitial fibrosis by Picrosirius staining,
and observed a significantly higher percentage of fibrosis in the
untreated group when compared with control and Hemin-treated
groups. This difference was more evident on polarized light
images, which more clearly show the presence of fibrotic regions
on kidney tissue (Figure 3A and 3C). Taken together, these results
show that Hemin induced HO-1 upregulation, and the increased
expression of this molecule offered renoprotection, as assessed by
protein excretion and Picrosirius staining of fibrotic tissue.
The induction of HO-1 decreases the expression of pro-
inflammatory and pro-fibrotic molecules
To examine the mechanisms that might be involved in the
functional and histological protection observed in Hemin-treated
animals, we analyzed the expression of pro-inflammatory and pro-
fibrosis-related molecules. In the Hemin-treated animals, there
was notably lower expression of TNF-a (Figure 4A), IL-6
(Figure 4B) and IL-1b (Figure 4C). In untreated animals subjected
to UUO, there was enhanced expression of MCP-1, but as
expected, lower transcription of this chemokine was observed in
Hemin-treated animals (Figure 4D). To corroborate these results,
we measured the protein expression of some pro- and antiin-
flammatory molecules. TNF-a, IL-1b, IFN-c and IL-6 were
augmented in UUO group, as well as the lymphoproliferative
cytokine IL-2. On the other hand, IL-10 was highly enhanced in
Hemin-treated animals (Figure 5, panels A, B, C, D, E and F). We
also looked for gene expression of catalase, an oxidative stress
Figure 6. HO-1 upregulation leads to less fibrotic and extracellular matrix gene expression as well as TGF-b protein production.
Relative mRNA expression (average 6 s.e.m.) of PAI-1 (panel A), collagen types I and III (panels B and C), fibronectin (panel D) and TGF-b (panel E).
Samples were obtained from obstructed kidneys of UUO and Hemin-treated groups. Gene expression from control animals was assigned a value of 1.
* p,0,05 vs. UUO. (F) TGF-b protein, assessed by ELISA assay, in obstructed kidney samples from UUO and Hemin-treated animals. The amount of
TGF-b quantified was divided by total tissue protein. * p,0,05 vs. Control and Hemin.
doi:10.1371/journal.pone.0014298.g006
HO-1 and Renal Fibrosis
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marker, and observed that in Hemin-treated group there was a
diminished amplification of this molecule, when compared to
UUO group (Figure S2, panel G). HIF-1a, a hypoxia marker was
also decreased in Hemin-treated group (Figure S2, panel H).
Next, we examined the gene expression of the pro-fibrotic
molecules, PAI-1 and TGF-b, and the extracellular matrix
proteins, type I and III collagens and fibronectin. We observed
that in Hemin-treated animals, there was lower expression of these
molecules, suggesting that HO-1 downregulated pro-fibrotic and
extracellular matrix-associated genes (Figure 6, panels A, B, C,
and D). Many of these pro-inflammatory and pro-fibrotic
molecules were increased after ureteral ligation, but in the
Hemin-treated group, this enhancement, when occurred, was
more attenuated than in the untreated UUO group. Interestingly,
although we noticed a more pronounced expression of TGF-b
mRNA in animals subjected only to UUO, when compared to
Hemin-treated animals, there was no statistical difference
(Figure 6E). However, when we performed the ELISA assay for
TGF-b, we observed notably higher protein production of this
cytokine in animals subjected only to UUO 14 days after surgery
compared to the Hemin-treated group (Figure 6F). Also, type I
collagen and FSP-1 (an EMT marker) were enhanced in animals
subjected only to UUO, which was not seen in the Hemin-treated
group (Figure 3B, 3D, and 3E). To further investigate the
mechanisms underlying this process, we performed an in vitro
assay, where HK-2 cells were treated with Hemin in presence or
not of TGF-b. TGF-b is well established inducer of EMT. In fact,
the down regulation of a-SMA in TGF-b-stimulated HK-2 cells
was prevented in Hemin pretreated cells. Moreover, Hemin did up
regulate HO-1 expression while maintained the epithelial
phenotype in TGF-b-stimulated HK-2 cells, as seen in E-cadherin
expression (Figure S1, panels C, D and E).
These results show that, in the Hemin-treated group, the
functional and structural protection observed in conjunction with
the upregulation of HO-1 was probably due to modulation of the
inflammatory response, which ultimately led to less fibrosis.
Hemin is able to restore renal function and to reverse
fibrosis when renal scars were already established
As we observed the ability of Hemin to prevent the initiation of
renal fibrosis, we further asked whether the induction of HO-1
could also reverse established tubule-interstitial disease. To
investigate this assertion, animals were treated with Hemin after
renal fibrosis was already established.
We quantified the mRNA of HO-1 and found that expression of
this enzyme was significantly higher in the Hemin-treated group at
14 days after UUO (Figure 7A). HO-1 protein production was also
higher in Hemin-treated animals, as shown in Figure 7B. We
found no difference in renal function and metabolic evaluation
between the groups (Table 1, Figure 8A and Figure S1, panels A–
F). However, we found a progressive proteinuria in untreated
animals, while the levels of urinary protein were maintained in
Hemin-treated animals. When animals were sacrificed, we
observed a significant decrease in proteinuria in the bladder and
in the obstructed pelvis in Hemin-treated animals compared to
animals subjected only to UUO (Figures 7C and 7D). After
running the SDS-PAGE for indirect quantification of urinary
albumin, we found that, although the initial levels of albuminuria
were similar between the groups, Hemin-treated animals showed a
significant reduction at 14 days (Figure 7E). Also, untreated
animals showed a significantly higher arterial blood pressure and
obstructed/contralateral kidneys weight ratio (Figures 8B and 8C).
Histological analysis also showed a higher percentage of fibrosis in
the animals subjected only to UUO when compared to Hemin-
Figure 7. Treatment with Hemin after established fibrosis upregulates HO-1 and improves renal function to that observed in
control animals 14 days post-obstruction. (A) HO-1 gene expression, evaluated by RT-PCR, of samples obtained from obstructed kidneys of
UUO and Hemin-treated animals. Kidney samples from normal rats were processed and used as control, with mRNA expression assigned a value of 1.
* p,0,05 vs UUO. (B) HO-1 protein production as assessed by Western Blotting from control, UUO and Hemin-treated groups. The top panel shows
the immunoblot of the HO-1 protein. The samples were also probed with a b-tubulin antibody as a control for the experiment. The graph represents
the digital optic quantification of HO-1 protein production divided by b-tubulin protein production. * p,0,05 vs. Control and # p,0,05 vs. UUO. (C)
Urine protein kinetics of control, UUO and Hemin-treated groups. UUO and Hemin groups underwent unilateral ureter obstruction and the latter
received the HO-1 inducer on days 6 and 7 after surgery. *p,0,05 vs. Hemin, # p,0,05 vs. Control and **p,0,05 vs. Hemin and UUO. (D) Urine
protein/creatinine ratio was calculated from the obstructed pelvis of UUO and Hemin-treated animals after 14 days. *p,0,001 vs. UUO. (E) Urine
albumin excretion analysis. The left panel represents an SDS-PAGE showing the molecular weight of albumin. The graph expresses the digital optic
quantification from the SDS-PAGE. The data are expressed as average 6 s.e.m.
doi:10.1371/journal.pone.0014298.g007
Figure 8. Role of Hemin treatment after 7 days of obstructed nephropathy on inulin clearance, mean arterial blood pressure and
kidneys weight. (A) Inulin clearance was estimated by 100 g of body weight (average 6 s.e.m.). No difference between the groups were observed.
(B) Mean arterial blood pressure were assessed during inulin clearance experiments (average 6 s.e.m.) * p,0,05 vs Control and Hemin. (C) After
sacrifice obstructed and contralateral kidneys were removed and weighed. After, a ratio between the kidneys were performed (average 6 s.e.m.).
* p,0,05 vs Control and # p,0,05 vs UUO.
doi:10.1371/journal.pone.0014298.g008
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treated animals. Indeed, Hemin-treated animals showed an impres-
sive two-fold decrease in the percentage of fibrosis. This striking
difference was more evident on Picrosirius staining, especially when
viewed as polarized light images (Figures 9A and 9B).
Reversion of fibrosis by upregulation of HO-1 was
associated with a decrease in pro-inflammatory and pro-
fibrotic molecule expression
We next determined whether treatment with Hemin after 7
days of UUO could also reduce the expression of pro-
inflammatory molecules. We observed an impressive upregulation
of the mRNA of pro-inflammatory cytokines in animals subjected
only to UUO. In the treated group, two of the main inflammatory
molecules, TNF-a and IL-6, were markedly decreased
(Figures 10A and 10B, respectively). The expression of IL-1b
was not different between the groups (Figure 10C). As macro-
phages play a central role in the progression of renal disease, we
analyzed MCP-1 expression, which is associated with macrophage
chemoattraction to the injured kidney. In the untreated group, we
observed a threefold increase in MCP-1 gene expression, and in
the Hemin-treated group, we saw a significant reduction in the
expression of this molecule (Figure 10D). Catalase and HIF-1a
gene expressions were also higher in untreated group (Figure S2,
panels I and J). The protein expression of pro- and antiinflamma-
tory cytokines were higher in untreated group (Figure 11, panels
A, B, C, D and E). IL-10 was slightly enhanced in Hemin-treated
group, when compared to UUO group, but presented similar
levels as compared to control group (Figure 11F).
As an inflammatory state can lead to fibrotic processes, we
analyzed the expression of the pro-fibrotic PAI-1 molecule, and
observed that treatment with Hemin reduced the expression of
PAI-1 when compared to animals subjected only to UUO
(Figure 12A). Furthermore, we observed impaired expression of
extracellular matrix-related proteins in animals treated with
Hemin: expression of fibronectin and types I and III collagen
was significantly lower in the Hemin-treated group as compared to
those animals subjected only to UUO (Figure 12, panels B, C, and
D). Indeed, type I collagen protein deposition, as well as FSP-1,
was notably decreased in the Hemin-treated group, as shown in
Figure 9.
Although we saw no difference in TGF-b mRNA between the
groups (Figure 12E), TGF-b protein production as assessed by
ELISA was significantly higher in the untreated group compared
to the Hemin-treated group (Figure 12F). These results show that
even with late treatment, HO-1 induced a decrease in molecules
associated with renal inflammation, as well as molecules
promoting fibrosis and extracellular matrix deposition, which
ultimately led to renal protection.
Discussion
In the present study, we tested two hypotheses: first, that
upregulation of HO-1, with a non-toxic dose of Hemin, could limit
the development of renal fibrosis and second, that HO-1 could
also, more importantly, reverse the progression of renal fibrosis,
once the scar was already established. Indeed, our data show that
upregulation of HO-1 has renoprotective functions in both
conditions, and that the mechanisms behind cytoprotection are
probably mediated by modulation of the inflammatory response.
The experimental model chosen by us was the UUO, that
despite not reproducing all features seen in renal fibrosis in
humans, it is fully reproducible and a widely used model [3,4,20].
This model allows us to design a strategy where we could treat the
animals when scar was already presented and quantified. UUO
leads to tubule-interstitial fibrosis in a process involving cellular
infiltration, tubular proliferation and apoptosis, (myo)fibroblast
Figure 9. Late treatment with Hemin also diminishes collagen deposition in obstructed kidneys. (A) Picrosirius staining and
Immunohistochemistry (IHC) for localization of FSP-1(panels g, h, and i) and Collagen type I (panels j, k, and l) in control, UUO and Hemin-treated
groups. Panels a, b, and c represent picrosirius staining, showing strong red staining in the UUO group, which was not seen in control or Hemin-
treated groups. The panels d, e, and f show the same image seen using polarized light. (B) Quantification of fibrosis, expressed as average 6 s.e.m.,
from the picrosirius staining shown in Figure 6A. * p,0,05 vs. Control and #p,0,001 vs. Hemin. (C) A representative graph showing IHC
quantification of FSP-1. *p,0,001 vs Control and Hemin and #p,0,05 vs Control. (D) IHC representative graph for Collagen type I. *p,0,001 vs
Control and Hemin and #p,0,05 vs Control.
doi:10.1371/journal.pone.0014298.g009
Figure 10. Induction of HO-1 after 7 days of UUO is capable of
reducing the signaling molecules involved in the inflammatory
process. Gene expression of TNF-a (panel A), IL-6 (panel B), IL-1b (panel C)
andMCP-1 (panel D) were assessed by RT-PCR (shown as average6 s.e.m.).
Samples were obtained from the obstructed kidneys of UUO and Hemin-
treated animals. Renal tissue was collected from animals that did not
undergo ureter obstruction surgery and were used as control. Messenger
RNA from control animals was assigned a value of 1. * p,0,05 vs. UUO.
doi:10.1371/journal.pone.0014298.g010
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accumulation, increased extracellular matrix (ECM) deposition
and tubular atrophy. A variety of mechanisms, including
immunological ones are involved in these processes. One
impressive advantage of this experimental model is that the
different features of the pathology appear rapidly, all within
around one week after the induction of the pathology, making
suitable to perform experimental approaches to halt the scaring
process. However, it is noteworthy to emphasize that the UUO
model has its known limitations. Some features classically present
in CKD in human is less prominent in UUO, which might limit
our conclusions. The data provide here should be careful
interpreted when considered other models of CKD.
Initially, we observed a significant amplification of HO-1
mRNA in Hemin-treated animals. UUO by itself is capable of
inducing HO-1 expression as observed by Moriyama and
colleagues [21] due to its ability to respond to cellular stress.
Moreover, it can rapidly be induced by exposure to a number of
factors, including ultraviolet radiation, hydrogen peroxide, heavy
metals, cytokines (IL-6, TNF-a, IL-10), and LPS [22,23,24,25].
Altogether, the inflammatory milieu and cell stress generated by
the obstruction might be responsible for the induction of HO-1.
Here, in this work, we optioned to induce HO-1 by treating the
animals with Hemin. This drug is widely used for this purpose for
a long time ago and its cytoprotective roles were recent reviewed
[26,27,28,29,30]. Indeed, Hemin was able to induce HO-1 in our
experiment in cells and in animals.
HO-1 has been shown to suppress some cellular processes that
participate in fibrosis in different animals models or in vitro systems
[31]. For this reason, we speculated that HO-1 would be a suitable
molecule to investigate in halting the progression of renal disease.
Here, we noticed progressive urinary protein excretion after
surgery, as observed in other experimental models of chronic
kidney disease [32,33]. These data demonstrated that the
contralateral (unobstructed) kidney also suffers from UUO,
possibly due to glomerular hyperfiltration and hypertension. We
also observed less urinary albumin excretion in the group treated
with Hemin that could be partially associated with the observed
reduction in arterial blood pressure.
Our study showed lower expression of pro-inflammatory molecules
in the Hemin-treated group. Previous work showed a positive
correlation between fibrosis and overexpression of TNF-a, IL-6 and
IL-1b in the UUO model [34,35,36]. In UUO, there is activation of
the renin–angiotensin system with production of reactive oxygen
species (ROS) and NFkB, which promote macrophage infiltration
[37], renal tubular apoptosis and interstitial fibrosis [38]. It may be
due to NFkB that inflammatory cytokines (TNF-a, IL-6 and IL-1b),
chemokines (MCP-1, MIP-1 and IL-8) and adhesion molecules
(ICAM-1, VCAM-1 and E-selectin) [39] were upregulated, similar to
that seen in our studies. Furthermore, activated macrophages can
generate TNF-a, which mediates pro-apoptotic signaling that leads to
renal tubular cell apoptosis following UUO [20]. HO-1 acts to release
antioxidant molecules such as bilirubin and ferritin, which can
neutralize the ROS produced mainly by infiltrating inflammatory
cells, resulting in less tissue damage.
Renal fibrosis results from an imbalance between synthesis and
degradation of extracellular matrix components, with enhanced
Figure 11. Late treatment with Hemin still maintains a dimished kidney protein expression (average± s.e.m.) of TNF-a (panel A), IL-
1b (panel B), IFN-c (panel C), IL-6 (panel D) and IL-2 (panel E) and increased protein expression of IL-10 (panel F). * p,0,05 vs UUO and
Hemin; # p,0,05 vs UUO.
doi:10.1371/journal.pone.0014298.g011
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production of types I and III collagens and fibronectin [40]. In our
study HO-1 upregulation decreased collagen deposition and FSP-
1 positive cells infiltrate, in accordance to another study which
demonstrated that animals subjected to UUO and then exposed to
low doses of CO had reduced a-SMA induction and less type I
collagen and fibronectin deposition [41]. Here, we cannot rule out
the effect of HO-1 on pelvic pressure. Indeed, pelvic pressure
could influence the fibrotic state. Previous works stated that on
early stages after the onset of UUO, intratubular pressure is
threefold elevated, and this reduces to an intermediate level by
24 h. But, sustained increases in tubular pressure are likely in this
model, once urine continues to pool as demonstrated by studies in
dogs [42,43].
Many pro-fibrotic molecules were described during renal
fibrogenesis. Matsuo et al described the role of PAI-1 in interstitial
fibrosis [44]. Moreover, Matsumoto et al also showed that HO-1-
deficient cells expressed higher PAI-1 levels and its significantly
reduction after treatment with bilirubin or CO [45]. In our study,
PAI-1 was also significantly reduced in Hemin-treated animals,
most at later time points. We also investigated the role of TGF-b,
since it is the main pro-fibrotic cytokine [46], and previous work
showed that inhibition of TGF-b attenuated renal interstitial
fibrosis in obstructive nephropathy [47,48]. TGF-b protein (its
active form) production was significantly enhanced in the group
subjected to UUO and that received no treatment. Conversely,
animals treated with an HO-1 inducer demonstrated significantly
less TGF-b expression, as seen by other works [9,49]. In the in vitro
assay, the presence of TGF-b enhanced mesenchymal and
decreased epithelial markers in proximal renal tubular cells, as
observed by others [50,51]. This situation was abolished when
Figure 12. Treatment with Hemin after UUO markedly downregulates gene and protein expression of molecules associated with
fibrosis. (A) Samples from obstructed kidneys of UUO and Hemin-treated animals were processed and RT-PCR for PAI-1(panel A), collagen types I
and III (panels B and C), fibronectin (panel D) and TGF-b (panel E) was performed (average6 s.e.m.). Gene expression in control animals was assigned
a value of 1. * p,0.05 vs. UUO. (F) ELISA assay for total TGF-b protein production in obstructed kidney from UUO and Hemin-treated animals. The
amount of TGF-b quantified was divided by total tissue protein. * p,0.05 vs. Control and Hemin.
doi:10.1371/journal.pone.0014298.g012
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cells were previous exposed to Hemin, suggesting a role for HO-1
in halting EMT process.
However, all the data presented up to now do not address the
issue of whether HO-1 could actually reverse established renal
fibrosis. In this context, we next evaluated the ability of Hemin
therapy administered post-UUO to reduce renal scar formation.
Our results clearly show that late treatment with Hemin still led to
upregulation of HO-1. The gene and protein expression of this
molecule were enhanced even 7 days after the drug were
administered, which confirms the effectiveness of the treatment.
In fact, the treated group, at sacrifice time, had the same renal
functional values as the control group. Furthermore, we observed
a striking reduction of inflammatory molecules in the treated
group. This is possibly due to the anti-inflammatory properties of
HO-1 byproducts. It is important to highlight, however, that late
treatment with Hemin was able to reduce the expression and
production of pro-fibrotic molecules, as well as type I collagen and
FSP-1 deposition on the injured kidney. Together, the results from
the delayed treatment with Hemin showed an impressive capacity
to reverse progressive renal disease. As patients with chronic
kidney disease usually begin treatment after established fibrosis,
this study is highly relevant to clinical practice, thus emphasizing
its importance.
Studies showing reversion of already established fibrosis have
become quite important, as EMT, a pivotal pathway for fibrosis
development, has been shown to be reversible. Previous work
showed that in a patient with diabetic nephropathy, a pancreas
transplant resulted in long-term normoglycemia and led to a
marked reduction in mesangial and mesangial matrix fractional
volumes [52]. Also, a recent study showed that, in a 5/6
nephrectomy model, delayed treatment with high doses of a type
1 angiotensin II receptor antagonist led to regression of
glomerulosclerosis, possibly by inhibiting PAI-1 and modulating
extracellular matrix turnover [53].
An in vitro study demonstrated that HO-1 upregulation could
prevent cyclosporine A-induced EMT via NRF2, a master
regulator of genes associated with the cellular antioxidant system
[54]. Kie et al also showed that HO-1 deficient mice subjected to
obstructive nephropathy had increased fibrotic tissue deposition,
as well as greater tubular TGF-b1 expression, inflammation, and
enhanced EMT [15]. These data corroborate our results and
suggest that HO-1 expression is important to attenuate EMT.
More importantly, HO-1 overexpression is able to reverse this
process.
HO-1 was able not only to protect the kidney from the onset of
progressive fibrosis but also, and more importantly, to reverse its
progression; HO-1-induced protection was evident in improved
renal functional outcome and lower expression of pro-inflamma-
tory and pro-fibrotic molecules. Taken together, we propose that
HO-1 induction might represent a promising therapy for limiting
chronic kidney disease.
Supporting Information
Figure S1 HO-1 upregulation is able to modulate fibrosis in
vitro. HK-2 cells were incubated with different doses of Hemin for
24 hours and Western Blotting was performed for HO-1 protein
expression. Panel A shows the image obtained from the blotting
and panel B represents its relative quantification. The same cells
were cultivated and treated with Hemin and/or TGF-Iˆ2 for 24
hours. After that, mRNA was extracted for later quantification by
Real Time PCR for the following molecules: HO-1 (panel C), Iˆ6-
SMA (panel D) and E-cadherin (panel E). Gene expression in
control cells was assigned a value of 1.
Found at: doi:10.1371/journal.pone.0014298.s001 (0.59 MB TIF)
Figure S2 Hemin treated animals present similar levels of serum
metabolic parameters than untreated ones, but show decreased
oxidative stress and hypoxic environment. The metabolic
evaluation is represented by pO2 (panel A), pCO2 (panel B),
Hematocrit (panel C), Serum Na+ (panel D), Serum K+ (panel E)
and Serum bicarbonate (panel F). mRNA expression of Catalase
and HIF-1Iˆ6 were performed by real time PCR from animals
submitted to UUO and treated or not with Hemin prior to surgery
(panels G and H, respectively), or 7 days after the surgical
procedure (panels I and J). All animals were sacrificed after 14
days of surgery. Gene expression in control animals was assigned a
value of 1.
Found at: doi:10.1371/journal.pone.0014298.s002 (0.41 MB TIF)
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